Literature DB >> 6619452

Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens.

D M Kemeny, M MacKenzie-Mills, M G Harries, L J Youlten, M H Lessof.   

Abstract

Antibodies to individual bee venom antigens were studied in detail in nine bee sting-allergic patients who received venom immunotherapy without side effects, in two patients who failed to reach maintenance, and in two whose sensitivity returned. The study was confined to patients who had IgE antibodies to at least one of four purified bee venom antigens at the start of treatment. IgE and IgG antibodies to phospholipase A2 (PLA2), hyaluronidase (HYAL), and acid phosphatase (ACID P) and IgE antibodies to melittin (MEL) were measured, and changes in the antibody levels were followed during bee venom immunotherapy. Two contrasting patterns of antibody response were seen in the nine successfully treated patients. In five patients there was a rise in serum IgG antibodies to the same antigens as the IgE antibodies. In two patients' serum IgE antibody to HYAL or ACID P fell without a marked IgG antibody response to these antigens, although high levels of IgG antibody to PLA2 were present in both. Although the first pattern is consistent with a "blocking" role for IgG antibody, clearly the second is not. Not all patients can be conveniently divided into these two categories, and two patients did not show any significant change in either IgG or IgE antibody but were nevertheless able to tolerate the maintenance dose of 100 micrograms of venom. Two patients who failed to reach the maintenance dose of 100 micrograms because of their allergic reactions to the injections of venom were distinguished by (1) very high serum IgE antibody and (2) a low ratio of IgG/IgE antibody. Passive immunization with IgG antibody from a hyperimmune beekeeper was, however, protective in these patients, although it did not raise their overall serum IgG antibody level very much. We are unable to explain either the failure of conventional therapy or the beneficial effect of passive immunization in these two patients. Two bee sting--allergic beekeepers lost their sensitivity to stings, but later, when their sera contained IgE antibody to another bee venom antigen, they reacted to stings and inhalation of beehive dander. These data suggest that either falling IgE antibody or IgG- "blocking" antibody could be responsible for providing clinical protection to bee venom--allergic subjects. Renewed clinical sensitivity was observed when the IgE response was modulated, with patients making IgE antibody first to one antigen and then to another.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6619452     DOI: 10.1016/0091-6749(83)90503-1

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

Review 1.  Can persistent IgE responses be suppressed?

Authors:  D M Kemeny; D Diaz-Sanchez
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking.

Authors:  Richard T Strait; Suzanne C Morris; Fred D Finkelman
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

Review 3.  Allergy and its mechanisms.

Authors:  M H Lessof
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-08

Review 4.  Current status of allergen immunotherapy (hyposensitization): memorandum from a WHO/IUIS meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

5.  Allergens of hymenopteran venoms.

Authors:  T P King; M D Valentine
Journal:  Clin Rev Allergy       Date:  1987-05

6.  Allergy to insect stings: a review.

Authors:  P W Ewan
Journal:  J R Soc Med       Date:  1985-03       Impact factor: 5.344

Review 7.  The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword.

Authors:  Jun Chen; William R Lariviere
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

8.  A systematic review and meta-analysis of HLA class II associations in patients with IgG4 autoimmunity.

Authors:  Anja Panhuber; Giovanni Lamorte; Veronica Bruno; Hakan Cetin; Wolfgang Bauer; Romana Höftberger; Astrid C Erber; Florian Frommlet; Inga Koneczny
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

9.  Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth.

Authors:  Neelesh R Soman; Steven L Baldwin; Grace Hu; Jon N Marsh; Gregory M Lanza; John E Heuser; Jeffrey M Arbeit; Samuel A Wickline; Paul H Schlesinger
Journal:  J Clin Invest       Date:  2009-08-10       Impact factor: 14.808

10.  MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.

Authors:  Inga Koneczny; Judith Cossins; Patrick Waters; David Beeson; Angela Vincent
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.